Skip to main content
TYK Medicines, Inc logo

TYK Medicines, Inc — Investor Relations & Filings

Ticker · 2410 ISIN · CNE100006L34 HKEX Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-12-01 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2410

About TYK Medicines, Inc

https://www.tykmedicines.com

TYK Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative small-molecule targeted therapies. The company leverages a proprietary small molecule drug design and screening platform, with a primary strategic focus on oncology, particularly treatments for lung cancer. The lead pipeline asset, TY-9591 (Edotamidine mesylate), an EGFR-targeted therapy, is currently in the Pre-NDA stage, having demonstrated promising clinical efficacy in treating lung cancer patients with brain metastasis. The pipeline also includes assets such as TY-302 and TY-2136, alongside multiple CDK inhibitors in clinical development, reflecting a commitment to addressing unmet medical needs in targeted cancer treatment.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is used to report movements in securities, including issued shares and treasury shares, on a monthly basis. While it tracks share capital, it is a standard regulatory filing for HKEX-listed companies to report monthly changes in securities, which falls under the 'Regulatory Filings' (RNS) category as it is a recurring compliance disclosure rather than a specific corporate action like a share buyback announcement (POS) or a capital change (SHA).
2025-12-01 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2025
Regulatory Filings Classification · 85% confidence The document is a statutory monthly return (Form FF301) filed with the Hong Kong Stock Exchange under Chapter 19B Listing Rules, detailing movements in registered share capital and issued shares. It is not an earnings release, management report, capital issuance notice, or AGM material, but rather a routine regulatory submission required by the exchange. There is no substantive change in share capital, and the form itself is the actual filing rather than an announcement of another report. It therefore best fits the fallback category of a general regulatory filing (RNS).
2025-11-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 95% confidence The document is a monthly return (Form FF301) filed by Namyue Holdings Limited to the Hong Kong Stock Exchange under Chapter 19B of the Listing Rules. It reports movements in authorised and issued shares, depositary receipts and confirms share capital status. This is not a financial report (10-K, IR, ER), management presentation, or dividend/merger notice, but a regulatory compliance filing. It falls into the general “Regulatory Filings” category (RNS) as it does not match any more specific classification.
2025-11-03 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 93% confidence The document is the Articles of Association of TYK Medicines, Inc., containing chapters on share issuance, board of directors, shareholders’ meetings, management, capital changes, and other internal governance provisions. This is a governance document detailing the company’s internal rules and board structure, matching the Governance Information category.
2025-10-30 English
POLL RESULTS OF 2025 SECOND EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 30, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is an announcement of poll results from an Extraordinary General Meeting, detailing the votes for ordinary and special resolutions. This fits the ‘Declaration of Voting Results & Voting Rights Announcements’ category, which covers official results from shareholder votes at any general meeting. Therefore, the correct classification is DVA.
2025-10-30 English
VOLUNTARY ANNOUNCEMENT - CLINICAL POSITIVE DATA FOR CDK INHIBITORS ANNOUNCED AT ESMO CONGRESS 2025
Regulatory Filings Classification · 80% confidence The document is a voluntary announcement by TYK Medicines publishing detailed clinical trial results for three CDK inhibitor candidates presented at a medical congress. It contains no financial results (earnings), no notice of dividends or share issues, no management changes, and no formal report filing (e.g., annual, interim). It is a standalone regulatory announcement that does not fit specialized categories such as Earnings Release (ER), Interim Report (IR), Investor Presentation (IP), or M&A Activity (TAR). Thus, it falls into the fallback category of a general regulatory filing (RNS).
2025-10-21 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.